Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
For Research Use Only. Not For Clinical Use.
Creative Biolabs provides world-class, cutting-edge recombinant antibodies targeting C5, essential for advancing biomedical research. Utilizing our state-of-the-art platforms, we ensure that our products meet the highest standards of quality and performance. Our commitment to accelerating research and discovery is reflected in our extensive range of recombinant products, each designed to offer exceptional value and reliability. Alongside our high-quality antibodies, we pride ourselves on delivering superior technical support to assist researchers at every stage of their work. With Creative Biolabs, you gain not only innovative solutions but also a dedicated partner in your scientific endeavors.
Target C5 is an important biological target. It is a large glycoprotein. In terms of its mechanism of action, C5 is involved in the complement system. When activated, it participates in a series of enzymatic reactions that lead to the formation of the membrane attack complex, which can cause damage to target cells. C5 plays a crucial role in the immune response and various physiological processes. Research on C5 is of great significance. It can help us better understand the mechanisms of immune-related diseases and provide potential targets for the development of new drugs. By studying C5, scientists can explore ways to modulate the immune response and treat diseases such as autoimmune disorders and inflammatory diseases. Additionally, understanding C5 may also contribute to the development of therapies for other conditions where C5 is involved.
Complement C5; C5D; C5a; C5b; ECLZB; CPAMD4
This gene encodes a component of the complement system, a part of the innate immune system that plays an important role in inflammation, host homeostasis, and host defense against pathogens. The encoded preproprotein is proteolytically processed to generate multiple protein products, including the C5 alpha chain, C5 beta chain, C5a anaphylatoxin and C5b.
We are committed to speeding up research and discovery by offering anti-C5 recombinant antibody products of the highest quality, excellent value, and top-notch technical support.
Cat. No. | Product Name | Target Species | Host Species | Applications |
TAB-008 | Anti-Human C5 Recombinant Antibody | Human | Human | ELISA; FC; IP; FuncS; IF; Neut; WB |
PABC-462 | Human Anti-C5 Recombinant Antibody (clone SKY59/RO7112689) | Human; Cynomolgus monkey | Human | WB; HA; ELISA; FC; Neut |
PABL-028 | Human Anti-C5 Recombinant Antibody (clone MEDI7814) | Human | Human | Neut; Inhib; FuncS |
HPAB-0128CQ | Mouse Anti-C5 Recombinant Antibody (clone BB5.1) | Mouse | Mouse | FC; IA; IF; IP; IHC; FuncS |
TAB-453CQ | Anti-Human C5 Recombinant Antibody (Tesidolumab) | Human | Human | ELISA; IHC; FC; IP; IF; FuncS |
To drive the progression of biopharmaceutical research and development to commercialization, our core values are set from a customer-oriented perspective, with the primary focus on meeting customers' demands for product quality. We have put in place a strict quality management system to guarantee our product quality. By meeting and even surpassing customer expectations, we aim to help our customers save time in drug development.
Fig.1 SDS-PAGE analysis of anti-C5 antibody
(Cat# HPAB-0128CQ, Creative Biolabs).
Fig.2 SEC-HPLC analysis of anti-C5 antibody
(Cat# HPAB-0128CQ, Creative Biolabs).
Fig.3 ELISA analysis of anti-C5 antibody
(Cat# TAB-453CQ, Creative Biolabs).
Fig.4 WB analysis of anti-C5 antibody
(Cat# PABC-462, Creative Biolabs).
Fig.5 DB analysis of anti-C5 antibody
(Cat# PABC-462, Creative Biolabs).
We have amassed years of expertise in recombinant antibody production and improvement. By providing top-notch service, we deliver recombinant antibody products of superior quality and a high standard in the briefest time frame.
Featured Anti-C5 Recombinant Antibody Production Platforms
Fig.6 Milligram-scale recombinant antibody production.
Fig.7 Gram-scale recombinant antibody production
Creative Biolabs is dedicated to offering researchers the most extensive and state-of-the-art high-quality recombinant antibodies in various formats. Our proficiency in recombinant antibodies encompasses a wide range of different engineering approaches. Our products are backed by excellent custom engineering services tailored to your specific needs.
Fig.8 Full Length Anti-C5 Recombinant Antibody Production and Modalities
Table 1. Therapeutic approaches targeting C5 in clinical development.
Research phase | Company | Classification | Indications | Details |
Launched - 2024 | Ra Pharma (UCB) | Drug Conjugates | Amyotrophic lateral sclerosis | This is a 15-mer macrocyclic peptide targeting complement C5 developed at UCB (after the acquisition of Ra Pharma in 2020). |
Launched - 2024 | Chugai Pharmaceutical | Biologics | Hemolytic uremic syndrome, atypical | It is a humanized monoclonal antibody against complement 5 (C5) developed by Chugai Pharmaceutical and Roche based on Chugai's Recycling Antibody® technology. |
Launched - 2023 | InflaRx | Biologics | Acute respiratory distress syndrome | It is an anti-complement factor C5a antibody developed at InflaRx. |
Launched - 2023 | Archemix | Drug Conjugates | Geographic atrophy | This is a pegylated aptamer targeting the C5 component of the complement cascade developed by IVERIC bio (formerly Ophthotech; now part of Astellas Pharma). |
Launched - 2019 | Generium | Biologics | Hemolytic uremic syndrome, atypical | It is a biosimilar of Alexion Pharmaceuticals' reference product Soliris(R), which was first launched in Russia in 2019 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). |
Launched - 2019 | Alexion Pharmaceuticals | Biologics | Acute kidney injury | This is a humanized monoclonal antibody against the complement component 5 (C5) developed by Alexion Pharmaceuticals. |
Registered - 2023 | Regeneron | Biologics |
Eye inflammation; Gastroenteropathy |
It is a human monoclonal antibody blocking complement C5 being developed by Regeneron. |
Phase III | Alexion Pharmaceuticals | Biologics | Dermatomyositis | This is a humanized bispecific minibody targeting albumin and human C5 in phase III clinical development at Alexion Pharmaceuticals for the treatment of generalized myasthenia gravis in adults with autoantibodies against acetylcholine receptor (AChR). |
Phase III | Alnylam Pharmaceuticals | Biologics | Complement-mediated disease | It is a small interfering RNA (siRNA) targeting complement C5 being developed by Alnylam Pharmaceuticals as a subcutaneous treatment for several complement C5-mediated disorders. Phase II clinical trials are ongoing for the treatment of primary immunoglobulin A nephropathy (IgAN), and phase I/II clinical trials for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). |
Phase III | Akari Therapeutics | Biologics |
Bullous pemphigoid Geographic atrophy |
This is a dual, protein-based inhibitor of complement C5 and leukotriene B4 (LTB4), is in phase III clinical development at Akari Therapeutics (formerly known as Volution Immuno Pharmaceuticals and Varleigh) for the treatment of bullous pemphigoid. |
Phase III | Alexion Pharmaceuticals | Biologics |
Myocardial infarction Restenosis |
It is a short-acting, recombinant C5 complement inhibitor, that had been in phase III clinical development for the treatment of patients experiencing acute myocardial infarction (AMI) who are treated with primary percutaneous coronary intervention (PCI). |
Phase II/III | InflaRx | Biologics |
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) |
This is a humanized monoclonal antibody directed against the human complement factor C5a in phase II/III clinical development at Staidson (Beijing) Biopharmaceuticals for the treatment of patients with severe COVID-19 and severe pneumonia, or acute lung injury/acute respiratory distress syndrome. |
Phase II | Kira Pharmaceuticals | Biologics | C3 glomerulopathy | It is a bifunctional antibody fusion protein, that is in phase II development at Kira Pharmaceuticals for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), systemic lupus erythematosus associated thrombotic microangiopathy (SLE-TMA), IgA nephropathy (IgAN), and C3 glomerulopathy (C3G). |
Phase II | Aptarion Biotech | Drug Conjugates |
Immunological Disorders; Inflammatory disorders |
This is a PEGylated mixed RNA/DNA L-configured aptamer targeting and neutralizing the complement component 5a (C5a) being developed by Aptarion Biotech as an immunomodulatory drug candidate. |
Should you require additional information regarding target C5, feel free to reach out to us via telephone or email. Our knowledgeable team is more than delighted to assist you in addressing any questions or challenges that may arise during your experiments, ensuring you have the support you need for successful research.